Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingcheng Lin

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Tumori|May 27, 2006
Downregulation of Epstein-Barr virus-encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cellsCaiwen Du, Bogui Wen, Derui Li, et al.
JAMA|December 17, 2014
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trialHe Huang, Xueying Li, Jun Zhu, et al.
The Oncologist|May 31, 2022
Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)Wenying Peng, Liming Cao, Likun Chen, et al.
Cancer Research and Treatment|October 5, 2018
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 TrialXueying Li, He Huang, Bing Xu, et al.
Targeted Oncology|May 3, 2026
Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA StudyLigang Xing, Jinming Yu, Xiangjiao Meng, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Tumori|May 27, 2006
Downregulation of Epstein-Barr virus-encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cellsCaiwen Du, Bogui Wen, Derui Li, et al.
JAMA|December 17, 2014
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trialHe Huang, Xueying Li, Jun Zhu, et al.
The Oncologist|May 31, 2022
Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)Wenying Peng, Liming Cao, Likun Chen, et al.
Cancer Research and Treatment|October 5, 2018
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 TrialXueying Li, He Huang, Bing Xu, et al.
Targeted Oncology|May 3, 2026
Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA StudyLigang Xing, Jinming Yu, Xiangjiao Meng, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 4